IME Share Price Performance
CA$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Imagin Medical Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
IME Community Narratives
There are no narratives available yet.
Recent IME News & Updates
Imagin Medical Inc. Key Details
Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.31
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -91.8%
Imagin Medical Inc. Competitors
Snowflake Analysis
About IME
- Founded
- 1986
- Employees
- n/a
- CEO
- WebsiteView website
Imagin Medical Inc., a urologic oncology company, focuses on the research, development, and commercialization of medical devices in the bio-chemistry industry. It offers the i/Blue Imaging System, which detects bladder cancer with advanced proprietary optics and light sensors; and enCage Coil, a disposable and focal therapy precision ablation device for use in the treatment of prostate cancer. The company is also developing technologies to visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. It has a license agreement with Lawrence Livermore National Security, LLC to develop and commercialize the i/Blue Imaging System. The company was founded in 1986 and is headquartered in Vancouver, Canada.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 10.0%
- 1 Year: 21.2%
- Year to Date: 19.9%
The market has been flat over the last week. Meanwhile, the market is actually up 21% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›